Clinical Trials & Research

The neurophysiology team at Arkansas Children’s is actively involved in research to find the best treatments for pediatric neurophysiological conditions. Our technicians take part in local, national and global investigations of new and existing treatments. This means your child has access to the most advanced care available, including the opportunity to participate in clinical trials when appropriate. The research activities of our team include:

Industry-Sponsored Studies

Use of ZX008 to treat Dravet Syndrome. A multicenter, randomized, double-blind, parallel group, placebo-controlled trial of two fixed doses of ZX008 (Fenfluramine Hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet syndrome.

Use of perampanel oral suspension in children with certain seizures. An open-label, multicenter study with an extension phase to evaluate the safety, tolerability, and exposure-efficacy relationship of perampanel oral suspension when administered as an adjunctive therapy in pediatric subjects (age 4 to less than 12 years) with inadequately controlled partial-onset seizures or primary generalized tonic-clonic seizures.

Use of perampanel for seizures associated with Lennox-Gastaut Syndrome. A multicenter, double-blind, randomized, placebo-controlled trial with an open-label extension phase of perampanel as adjunctive treatment in subjects at least 2 years of age with inadequately controlled seizures associated with Lennox-Gastaut Syndrome.

Use of cannabidiol in patients with Tuberous Sclerosis. Use of SAGE-547 for super-refractory status epilepticus. The STATUS Trial to evaluate SAGE-547, an investigational medication for super-refractory status epilepticus (SRSE).